

**Non-surgical Interventions for  
The Non-operated Back Pain Patient**

An update for primary care providers  
Developed by an educational grant from SPR Therapeutics

Lumbar Spine X-Ray © iStockphoto.com  
All rights reserved. Licensed under CC BY  
4.0

1

---

---

---

---


---

---

---

---

**Speaker Title and Affiliation**



Michael Fishman, MD, MBA

Pain Medicine Physician &  
Director of Research  
Center for Interventional Pain & Spine  
Lancaster County, PA

2

---

---

---

---


---

---

---

---

**Disclosures**



**Consultant/Independent Contractor:**  
Abbott, Braeburn, Biotronik, Cornerloc, IMSE, Medtronic, Nevro

**Grant/Research Support:**  
Research payments were made to my institution related to clinical trial work from  
Abbott, Biotronik, Cornerloc, Lumbrera, Medtronic, Nalu Medical, Seikagaku,  
Thermaquil, and Boston Scientific

**Honoraria:**  
North American Neuromodulation Society

3

---

---

---

---

---

---

---

---

### Learning Objectives



- Identify therapy options that may guide referral to an interventional pain management physician skilled in newer procedures.
- Describe how to incorporate patient preference when developing a shared patient- centered care pathway
- Describe the pain treatments that may be appropriate for pain that is specific to a certain set of low back pain conditions

---

---

---

---

---

---

---

---

4

### Agenda



- Epidemiology and prognosis
- Treatment challenges and limitations of common therapies
- Newer minimally invasive interventions for virgin (non-operated) back pain
- Patient treatment preferences
- LBP treatment algorithm

---

---

---

---

---

---

---

---

5


### Impact of Low Back Pain (LBP)



- #1 cause of global years lived with disability (YLD)<sup>1</sup>
- 7.3% global point prevalence (activity-limiting)<sup>2</sup>

**80%**  
of adults have LBP at  
some point<sup>3</sup>

**\$200 B**  
Est. annual cost of  
LBP in U.S.<sup>3</sup>



1. *N*eu *L*ancet 2016  
2. *H*atipoglu *L*ancet 2016  
3. *B*uick *W*orld *O*id 2007

---

---

---

---

---


---

---

---

6

### Prognosis in LBP



- 90% of acute LBP patients recover...
- ...but recurrence is common!
- ~10% develop chronic back pain<sup>1</sup>

Acute      Sub-acute      Chronic

4 weeks      12 weeks

1. Mascal Rev Saúde Pública 2015

---

---

---

---

---


---

---

---

7

### LBP Patients in Primary Care



**Epidemiology is often unclear**

- Axial pain is non-specific in ~70% of LBP patients
- SI joint pain occurs in ~20% of LBP patients<sup>1</sup>
- Lumbar Spinal Stenosis (LSS) occurs in ~10% of LBP patients and is more common in the elderly<sup>2</sup>

1. Cohen Esquith J Pain Medicine 2018  
2. Johnson Osteoporosis Care Page 2012

---

---

---

---

---


---

---


---

8

### The Urgency of Appropriate Pain Treatment



- Unchecked nociceptive inputs can change the CNS, resulting in hypersensitivity to pain (central sensitization)<sup>1</sup>
- Imaging reveals brain structures are involved<sup>2</sup>
- Potential for peripheral *and* central pain generators in LBP a present significant treatment challenges<sup>3</sup>
- Central Sensitization → Chronicity



1. Waddell Pain 2011  
2. Kumar Nat Rev Neurosci 2017  
3. Abigail P 1000Research 2016

---

---

---

---

---


---

---


---

9

### LBP and the Opioid Crisis



- 20% of LBP patients still fill an opioid Rx<sup>1</sup>
- Little evidence of efficacy in chronic LBP<sup>2</sup>
- Non-pharma treatments needed for LBP
- Non-surgical interventions can reduce opioid intake



**Opioids**

1. Rand J. Am Board Fam Med 2020  
2. Deyo BMJ 2015  
3. Global Spine Society of Regional Anesthesia and Pain Medicine November 2019  
4. Anesthesiology Pain Med 2018

10

---

---

---

---


---

---

---

---

### Bottom Line



We need novel interventional treatments that are patient friendly and effective!

11

---

---

---

---



---

---

---

---

### Conventional Treatments

The diagram illustrates conventional treatments for LBP on a spectrum. On the left, under 'LESS effective', are NSAIDs, PT, and Opioids. In the center, under 'More Effective', is Ablation. On the right, under 'MORE Invasive', are Injections, Surgery, and Permanent Implant. A central box highlights 'Less Invasive' and 'More Effective' treatments.

12

---

---

---

---


---

---

---

---

### Long-standing Therapies: Injections



**Pain Management Injection Therapies for Low Back Pain, AHRQ 2015<sup>1</sup>**

Radiculopathy	Immediate, small, short-term, improvements common
Spinal Stenosis, facet joint pain	Evidence suggests that epidural/facet joint corticosteroid injections are not effective
SI joint pain	Insufficient evidence to evaluate effectiveness

**Bottom Line: Low Risk, Minimal Benefit**

1. Chou AHRQ 2015

---

---

---

---

---


---

---


---

13

### Long-standing therapies: RFA



- RFA = Radiofrequency Ablation
- Used for >20 years
- Denervates select peripheral nerves with heated needle probe
- Typically involves repeated procedures



Medial Branch RFA/Denervation

Adapted from: <http://www.physiotherapy.com.au/health-professionals/physiotherapy/medial-branch-nerve-lesioning-for-the-treatment-of-low-back-pain/>

---

---

---

---

---


---

---

---

14

### Meta-analysis of RFA for LBP<sup>1</sup>



- Provides minimal effect on VAS pain score
- Longer-term effectiveness is uncertain
- Can result in paraspinal muscle degeneration
- While medial branch is <1mm in diameter, lesion created is significant (up to ~600 mm<sup>3</sup>)<sup>2</sup>

**RFA guidelines<sup>3</sup> recommend discussing risk and alternative therapies with patients**

	Trials		Pain Reduction (10 point scale)
		n	
<b>RFA of facet joints</b>			
1-3 mo	7	599	-0.56
6 mo	4	361	-0.66
12 mo	2	291	-0.72
<b>RFA of sacroiliac joints</b>			
1-3 mo	5	384	-1.53
6 mo	1	228	-0.28
12 mo	1	228	-0.19
<b>RFA of intervertebral discs</b>			
1-3 mo	4	200	-0.98
6 mo	3	127	-1.74
12 mo	1	20	-1.70

1. Chappell BM 2020  
2. Cedeno, et al Pain Physician 2017  
3. Cohen Reg Anesth Pain Med 2020

---

---

---

---

---


---

---

---

15

### Healthy Multifidus, Healthy Back?



More than just an interesting correlation?

- Low back pain is non-specific in ~70% of LBP patients
- Lumbar multifidus muscle atrophy is present in ~80% of LBP patients

Potential benefits of a contracting multifidus:

- Proprioceptive cues from multifidus contractions may be important in maintaining low back health ("exercise is health")
- Many low back pain patients are unable (or unwilling) to perform low back exercises

Medial branch nerve provides:

- sensory innervation of facet joints
- motor innervation to multifidus, a core stabilizer of the spine

**Should we wait to ablate?**

---

---

---

---

---


---

---

---

16

### More on Multifidus and Low Back Pain



- The prolonged absence of multifidus activity and contractility reduces proprioceptive central feedback
- The absence of proprioceptive feedback may cause pain to be centralized even after the original pain generator heals
- Centralization of pain may explain why LBP is so often non-specific
- Increasing healthy peripheral inputs from contracting muscle may increase proprioceptive inputs and reverse central sensitization

Injury/Onset of Pain

Artrogenic Inhibition

Reduced Multifidus Contraction

Atrophy and Fatty Infiltration

Reduced Central Proprioceptive Feedback

Central Hypersensitivity and Centralization of Pain

Pain Becomes Non-specific

---

---

---

---

---


---

---

---

17

### Interventional Sub-indication Targets in LBP



	Lumbar Spinal Stenosis (LLS)	Sacroiliac Joint Pain	Vertebrogenic Pain	Axial Pain
<b>Symptoms</b>	Pain in back/legs/buttocks when standing; relief when sitting	Pain over SI joint, often with leg pain; commonly aggravated by walking and stairs	Localized back pain, no leg pain; MRI indicates Type I/II Modic changes	Localized back pain, no leg pain
<b>Causes</b>	Ligamentum flavum hypertrophy, disc bulging or foraminal narrowing impinging on spinal cord nerves	Damage or injury to SI joints	Vertebral endplate damage	Evidence of clear pain generator may be unclear; central sensitization is common

---

---

---

---

---

---

---

---

18

### Lumbosacral Spinal Stenosis (LSS) Interventions

Approaches:

- **Debulk hypertrophic ligamentum flavum encroaching on spinal cord nerves (PILD procedure)**
- **Insert spinal spacers to reduce stenosis associated with intervertebral foraminal encroachment upon extension**

Koga, Minimally Invasive Surg 2017;1:3-5

19

---

---

---

---

---

---

---

---

---

---

### LSS Intervention – Debulking of Ligamentum Flavum

Improvements in Oswestry Disability Index (ODI) and Patient Satisfaction with Epidural Steroid Injections (ESI) Versus Percutaneous Image-guided Lumbar Decompression (PILD)

Time Point	ESI ODI	PILD ODI	ESI Satisfaction	PILD Satisfaction
6 months	62.2%	35.7%	64.8%	30.2%
12 months	58.0%	27.1%	61.5%	33.3%

No difference in safety between PILD and ESIs

Champlin, Fish Physician 2016

20

---

---

---

---

---

---

---

---

---

---

### LSS Intervention – Interspinous Spacer Implant

**Before**      **After**

21

---

---

---

---

---


---

---

---

---

---



22

---

---

---


---

---

---

---

---



23

---

---

---


---

---

---

---

---



24

---

---

---

---

---


---

---

---



### SI Joint Interventions: Fusion/Stabilization



**Pain:** Non-surgical Management (NSM) vs Minimally invasive fusion

**Disability:** Non-Surgical Management (NSM) vs Minimally invasive fusion

Multiple treatment options exist, some without long term data

1. Polly et al J Spine Surg 2016

25

---

---

---

---

---

---


---

---

---

---

### Vertebrogenic LBP



Intraosseous nerves within the vertebral body were first described in 1998

The vertebral endplates can be a source of pain

Pain is generally accompanied by Type 1 or Type 2 Modic changes on MRI

- Modic type I changes are related to bone marrow edema and inflammation signifying acute degenerative changes in the vertebral end plate.
- Modic type II changes signify fatty degeneration of the bone marrow.

Adapted from: <http://www.spinejournal.com/2016/08/01/vertebrogenic-lbp>

26

---

---

---

---

---

---


---

---

---

---

### Axial LBP Treatments: Basivertebral Nerve Ablation



Mean ODI Over Time

Mean VAS Over Time

ODI decrease of 67% in patients with a 5 year follow-up

VAS decrease of 63% in patients with a 5 year follow-up

1. Fischgrund et al J Spine Surg 2020

27

---

---

---

---

---

---

---



---

---

---

### Axial LBP Intervention: 60-day Medial Branch PNS

Peripheral nerve stimulation (PNS) of the medial branch nerve

- Medial Branch PNS induces cycling tension within the multifidus muscle
- Multifidus contractions induce activation of afferent (sensory and proprioceptive) signals terminating in the cortex

---

---

---

---

---

---



---

---

28

### Axial LBP Intervention: 60-day Medial Branch PNS

Peripheral nerve stimulation (PNS) of medial branch nerve, for up to 60 days


---

---

---

---

---

---


---

---

29

### Axial LBP Intervention: 60-day Medial Branch PNS

Pain relief often endures well beyond treatment period<sup>1</sup>




63% avg. pain reduction among responders

**Opioid Use\***

73% ≥50% reduction in opioids


- Average 23 MME reduction among responders



**Pain†**

64% ≥50% pain relief


- Average 70% reduction among responders



**QoL**

82% ≥ 10-pt reduction


- Average 26-pt reduction among responders



**Pain Interference\***

82% ≥ 30% reduction

- Average 69% reduction among responders



1. Gilmore Pain Panel 2019  
2. Gilmore ASPN 2019

---

---

---

---

---

---

---

---

30

### Considering PNS Versus RFA

When is multifidus preservation important?

- A. In the younger patient to minimize multifidus atrophy?
- B. In the older already atrophic patient?
- C. A and B

It's in both populations, of course!

Level	Under 40	Over 40
L4	18%	52%
L5	52%	82%

Ekin et al, Diagn Intervent Radiol 2016; 22: 273-276

31

---

---

---

---

---

---

---

---

---

---

### Patient Preference Survey (n=347)

- Survey of patients (aged 34–75) with activity-limiting moderate-to-severe axial back >6 months duration
- Potential complications include:
  - For RFA:
    - Multifidus denervation
  - For 60-day PNS:
    - Potential for 100-micron lead fracture
- **Patients overwhelmingly preferred PNS as a motor-sparing option**

Option	Percentage
60-day PNS	45.8%
Radiofrequency ablation	28.0%
Neither	26.2%

P=0.001

\*Gulak, et al. Network your Pain Strategy. Presented at American Academy of Pain and Neuroscience webinar, August 2020.

32

---

---

---

---

---

---

---

---

---

---

### Axial LBP Intervention: Permanent PNS Implant

Medial branch stimulation delivered for two 30-minute sessions daily in which the patient is lying prone

Permanently Implanted Medial Branch Stimulation Leads

Permanently Implanted Pulse Generator

33

---

---

---

---

---


---

---

---

---

---



34

---

---

---

---

---


---

---

---

---

---



35

---

---

---

---

---


---

---

---

---

---



36

---

---

---

---

---


---

---

---

---

---



37

---

---

---


---

---

---

---

---



39

---

---

---


---

---

---

---

---



41

---

---

---

---


---

---

---

---

### LBP Interventional Treatment Safety Summary



	Debulking Intervention <sup>1</sup>	Interspinous Spacer <sup>2</sup>	60-day PNS <sup>3</sup>	Permanent PNS <sup>4</sup>	Spinal Cord Stimulation <sup>5</sup>
Serious Adverse Event* Rate (%)	0.0%	8.4%	0.0%	11.0% <sup>6</sup>	9.0% <sup>6</sup>

\*Procedure - or device-related  
<sup>1</sup>Rate of surgical interventions required

1. *Chiropractic Pain Physician* 2016  
 2. *Pain* 2016;25(10):2356-2367  
 3. *Spine* 2016;41(1):113-118  
 4. *Neurology* 2016;86(24):2163-2171  
 5. *Spinal Cord* 2016;54(10):1053-1061  
 6. [http://www.accessdata.fda.gov/drugsatfd\\_docs/nda/nda030822s01.pdf](http://www.accessdata.fda.gov/drugsatfd_docs/nda/nda030822s01.pdf)

42

---

---

---

---

---

---

---

---


---

---

---

---

### Summary



- 1) Begin conservative...work your way up through invasiveness
- 2) Opioids are not conservative!
- 3) Many new FDA-cleared LBP interventional treatment options exist
- 4) Patients generally prefer treatments that do not involve permanent implants or motor impairment
- 5) Confirm whether the pain physician you choose to refer to is aware of and trained to offer any number of the minimally invasive interventions now available

43

---

---

---

---

---

---

---

---


---

---

---

---

### References



- Vos T, Allen C, Arora M, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet*. 2016;388(10053):1545-1602.
- Harvigsen J, Hancock MJ, Kongstad A, et al. What low back pain is and why we need to pay attention. *Lancet*. 2018;391(10137):2356-2367.
- Rubin DI. Epidemiology and risk factors for spine pain. *Neuro Clin*. 2007;25(2):353-371.
- Meucci RD, Faesa AG, Faria MMX. Prevalence of chronic low back pain: systematic review. *Rev Saude Publica*. 2015;49:73.
- Cohen SP. Sacroiliac joint pain. In: *Essentials of Pain Medicine*. Elsevier; 2018:601-612. e602.
- Ishimoto Y, Yoshimura N, Muraki S, et al. Prevalence of symptomatic lumbar spinal stenosis and its association with physical performance in a population-based cohort in Japan: the Wakayama Spine Study. *Osteoarthritis Cartilage*. 2012;20(10):1103-1108.
- Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. *Pain*. 2011;152(3 Suppl):S2-S15.
- Kurer R, Fior H. Structural plasticity and reorganization in chronic pain. *Nat Rev Neurosci*. 2017;18(1):20.
- Allegri M, Montella S, Salici F, et al. Mechanisms of low back pain: a guide for diagnosis and therapy. *F1000Research*. 2016;5.
- Raad M, Pakpour J, Harris AB, et al. Opioid Prescriptions for New Low Back Pain: Trends and Variability by State. *J Am Board Fam Med*. 2020;33(1):38-42.
- Dayo RA, Von Korf M, Dahnke D. Opioids for low back pain. *BMJ*. 2015;350.
- Gilmore C, Kapural L, Hopkins T, et al. Reductions in Opioid Consumption with Percutaneous Nerve Stimulation (PNS) for Chronic Low Back Pain. Poster presented at: 18th Annual Meeting of the American Society of Regional Anesthesia and Pain Medicine, 2019 Nov 14-16, New Orleans, LA.
- Al-Kaisy A, Palmisani S, Smith TE, et al. Long-term improvements in chronic axial low back pain patients without previous spinal surgery: a cohort analysis of 10-kHz high-frequency spinal cord stimulation over 36 months. *Pain Med*. 2018;19(6):1219-1226.
- Chou R, Hashimoto R, Friedly J, et al. Pain management injection therapies for low back pain [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2016 Feb. (Comparative Effectiveness Reviews, No. 169.)
- Chappell ME, Lashman R, Trotter P, Abrahams M, Lee M. Radiofrequency denervation for chronic back pain: a systematic review and meta-analysis. *BMJ open*. 2020;10(7):e0035540.
- Cedeno DL, Vallejo A, Kelley CA, Tilley DM, Kumar N. Comparisons of lesion volumes and shapes produced by a radiofrequency system with a cooled, a protruding, or a monopolar probe. *Pain Physician*. 2017;20(8):E915-E922.

44

---

---

---

---

---

---

---

---

---

---

---

---

### References



- Cohen SP, Bhaskar A, Bhalta A, et al. Consensus practice guidelines on interventions for lumbar facet joint pain from a Multispecialty, International Working group. *Reg Anesth Pain Med.* 2020;45(6):424-467.
- Koga H. Improved percutaneous endoscopic translaminar approach for lumbar foraminal stenosis at L5/S1. *Mini-invasive Surg.* 2017;1:3-5.
- Champagne J, Centers P, Shrivastava N, Hopkins J, Benjamin R. MILDIB is an effective treatment for lumbar spinal stenosis with neurogenic claudication: MIDAS ENCORE randomized controlled trial. *Pain Physician.* 2016;19:229-242.
- Patel VV, Whang PG, Haley TR, et al. Superior interspinous process spacer for intermittent neurogenic claudication secondary to moderate lumbar spinal stenosis: two-year results from a randomized controlled FDA-IDE pivotal trial. *Spine (Phila Pa 1976).* 2015;40(6):275-282.
- Polly DW, Swofford J, Whang PG, et al. Two-year outcomes from a randomized controlled trial of minimally invasive sacroiliac joint fusion vs. non-surgical management for sacroiliac joint dysfunction. *International journal of spine surgery.* 2016;10.
- Fischgrund JS, Rhyne A, Franke J, et al. Intracapsular basivertebral nerve ablation for the treatment of chronic low back pain: 2-year results from a prospective randomized double-blind sham-controlled multicenter study. *Int J Spine Surg.* 2019;13(2):110-119.
- Gilmore CA, Kapural L, McGee MJ, Boggs JW. Percutaneous Peripheral Nerve Stimulation for Chronic Low Back Pain: Prospective Case Series With 1 Year of Sustained Relief Following Short-Term Implant. *Pain Pract.* 2020;20(3):310-320.
- Ekin EE, Yildiz MK, Mutlu H. Age- and sex-based distribution of lumbar multifidus muscle atrophy and coexistence of disc hernia: an MRI study of 2028 patients. *Diagn Interv Radiol.* 2018;22(3):273.
- Gulati, et al. Rethink your Pain Strategy. Presented at: American Academy of Pain and Neuroscience webinar, August 2020.
- Gilmore CA, Ilfeld BM, Rosenow JM, Li S, Desai MJ, Hunter CW, Rauck RL, Nader A, Mak J, Cohen SP, Crosby ND, Boggs JW. Percutaneous 60-day Peripheral Nerve Stimulation Implant Provides Sustained Relief of Chronic Pain Following Amputation: 12-month Follow-Up of a Randomized, Double-Blind, Placebo-Controlled Trial. *Regional Anesthesia and Pain Medicine.* 2019.
- [https://www.accessdata.fda.gov/cdrh\\_docs/pdf13P130022b.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf13P130022b.pdf)

---

---

---

---

---

---

---

---

---

---

---

---

45

Thank you!




---

---

---

---

---

---

---

---

---

---

---

---

46